EUVIMEDEUVIMED entdecken
Leitlinie

Managing hyperkalemia in patients with heart failure on guideline-directed medical therapy: challenges and opportunities

Giorgio Gentile, Jahid Hossain, Erberto Carluccio, Gianpaolo Reboldi iD

Internal and Emergency Medicine · 2024

DOI: 10.1007/s11739-024-03571-1 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Internal and Emergency Medicine, 2024. Verfasst von Giorgio Gentile und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Royal Cornwall Hospitals NHS Trust, Truro, UK. Hauptthemen laut MEDLINE: Heart Failure, Hyperkalemia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heart failure is a chronic and invalidating syndrome that affects tens of millions of people worldwide with significant socio-economic ramifications for the health care systems. Significant progress in the understanding of the pathophysiology of heart failure has allowed the gradual introduction of several drug classes for the management of such patients. Beta-blockers, mineralocorticoid receptor antagonists, angiotensin receptor neprilysin inhibitors, and sodium-glucose-cotransporter 2 inhibitors are all considered pillars of the guideline-directed medical therapy for heart failure. Despite remarkable improvements in the morbidity and mortality of heart failure, however, many patients still develop clinically significant hyperkalemia during combined treatment with those four pharmacological pillars. The consequence is often a down-titration or discontinuation of one or more crucial drugs, which in turns leads to a considerable increase in the risk of cardiovascular events, dialysis, and all-cause mortality. This paper will explore novel approaches for the management of hyperkalemia in heart failure, including closer monitoring of potassium levels, early review of drugs that might increase the risk of hyperkalemia, and pharmacological treatment of hyperkalemia, with a special emphasis on sodium-glucose-cotransporter 2 inhibitors and potassium-binding agents, including patiromer and sodium zirconium cyclosilicate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureHyperkalemiaHumansAdrenergic beta-AntagonistsMineralocorticoid Receptor AntagonistsPolymersPractice Guidelines as TopicSilicatesSodium-Glucose Transporter 2 Inhibitors

Stichwörter der Autor:innen

FinerenoneHeart failureHyperkalemiaPatiromerSodium zirconium cyclosilicateSodium–glucose-cotransporter 2 inhibitors

Substanzen

Adrenergic beta-AntagonistsMineralocorticoid Receptor AntagonistsPolymersSilicatesSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Nephrology, Royal Cornwall Hospitals NHS Trust, Truro, UK.
  • College of Medicine and Health, University of Exeter, Exeter, UK.
  • Department of Medicine and Surgery, University of Perugia, Piazza Lucio Severi, 1, 06132, Perugia, Italy.
  • Department of Medicine and Surgery, University of Perugia, Piazza Lucio Severi, 1, 06132, Perugia, Italy. paolo.reboldi@unipg.it.

ORCID-Profile: Gianpaolo Reboldi

Zitieren

APA

Gentile, G., Hossain, J., Carluccio, E., & Reboldi, G. (2024). Managing hyperkalemia in patients with heart failure on guideline-directed medical therapy: challenges and opportunities. Internal and Emergency Medicine. https://doi.org/10.1007/s11739-024-03571-1

Vancouver

Gentile G, Hossain J, Carluccio E, Reboldi G. Managing hyperkalemia in patients with heart failure on guideline-directed medical therapy: challenges and opportunities. Internal and Emergency Medicine. 2024. doi:10.1007/s11739-024-03571-1

BibTeX
@article{Gentile2024,
  author = {Gentile, Giorgio and Hossain, Jahid and Carluccio, Erberto and Reboldi, Gianpaolo},
  title = {Managing hyperkalemia in patients with heart failure on guideline-directed medical therapy: challenges and opportunities},
  journal = {Internal and Emergency Medicine},
  year = {2024},
  doi = {10.1007/s11739-024-03571-1}
}
Kostenlos starten →